



### **Invetech Expands its Service Offering into the Drug Discovery Market**

(SAN FRANCISCO, CA – 24 September 2007) Invetech, a worldwide leader in the development of biomedical instruments and automated research & manufacturing processes, has extended its innovative service offering to the drug discovery market. The company's expertise crosses a number of disciplines crucial to the drug discovery process including liquid handling, plate handling, robotics, software interfaces, optics, specialized detection systems, miniaturization and integration.

Identifying the best commercial direction for clients is Invetech's principal goal. Taking a holistic approach from concept through to market, the company works collaboratively with its clients to deliver an integrated range of instrument development, custom automation and systems integration services. Engineering is tightly coupled with in-house application science to enable field representative product testing during the development process. In-house bio-safe laboratories are available for testing of early prototypes with real samples in a representative environment, and for subsequently supporting replicated systems at client sites globally.

Jari Palander, Vice President of North American Operations at Invetech, comments: "Invetech is capable of handling difficult challenges - our scale, breath of expertise and skills, and diverse project experience enables us to think out-of-the-box and uncover innovative, proprietary solutions and integrate these with our clients' new and existing systems."

Invetech's track record builds on thousands of development projects worldwide. The company has recently demonstrated its expertise with the development of the base technology with complex multi-lane microfluidics on a silicon based fluidics chip. In a matter of months, Invetech designed a proprietary drug discovery platform on that base technology, integrating commercial autosamplers with complex fluidics and high performance fluorescence cellular imaging. The final system enabled previously unfeasible cellular assays for cell apoptosis and ADME/Tox analysis. In another case, Invetech was asked to develop an in-house high throughput screening platform on behalf of a leading North American company. Working in close collaboration with the client's technology R&D department enabled Invetech to enhance the design of the system and replicate it for supply to global divisions.

For more information about Invetech's innovative instrument development and custom automation services, please contact Invetech on [instruments@invetech.us](mailto:instruments@invetech.us), visit the website [www.invetech.us](http://www.invetech.us), or phone East Coast US: +1 203 675 4502, West Coast US: +1 415 533 1958.

**- ENDS -**

For further press information please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email [invetech@scottpr.co.uk](mailto:invetech@scottpr.co.uk)

Invetech Pty Ltd, 495 Blackburn Road, Mt Waverley Vic 3149, Australia. Phone +613 9211 7713, Fax +613 9211 7703. Email: [instruments@invetech.us](mailto:instruments@invetech.us) Web: [www.invetech.us](http://www.invetech.us)



**About Invetech:**

For more than 20 years Invetech has been at the forefront of new product development and automation. With experience drawn from over 5,000 projects, Invetech delivers global contract design and development, contract instrument manufacturing and custom automation services to life sciences, drug discovery and pharmaceutical companies, in addition to 7 of the world's top 10 clinical diagnostic companies.

Invetech combines its integrated in-house capabilities, specialist knowledge and diverse experience to deliver better solutions, in the shortest possible time and with less risk, to its clients base of start-ups through to multinationals. Its commercial focus, responsive and flexible approach, and unbiased solutions, means clients get the best outcome with the aim of commercial success.